Clinical DevelopmentThe Phase 1 trial investigating TH103, a long-acting anti-VEGF agent, for neovascular age-related macular degeneration is progressing as planned.
Financial StabilityAfter closing the reverse merger with AlloVir, Kalaris ended the first quarter with $101 million in cash and equivalents, which provides runway into the fourth quarter of 2026, beyond the top-line readout from the Phase I study of TH103, and potential initiation of a Phase II study in 2026.
Market OpportunityTH103 has the potential to offer better outcomes and longer treatment intervals than current anti-VEGF therapies for the treatment of retinal vascular diseases, which represents a roughly $15 billion market globally.